The investigational GLP-1 receptor agonist MET-097i, which may be able to be dosed just once a month, yielded weight loss of ...

Affordability and access drive "gray," says Sabina Hemmi, founder of GLP Winner, a consumer watchdog. Some microdose the at-home concoctions as a cost-effective maintenance regimen. Others use these ...

The Rise of GLP-1 Injections in Weight Loss In our fast-paced world, the quest for weight loss has become increasingly prevalent. Individuals are exploring various methods, from diet regimens to gym ...

Crinetics Pharmaceuticals gains FDA approval for PALSONIFY, targeting key unmet needs in Acromegaly. Click here to read my ...

Paltusotine (Palsonify; Crinetics), a novel nonpeptide somatostatin receptor type 2 nonpeptide (SST2) agonist, was approved by the FDA for the treatment of acromegaly in adults who had an inadequate ...

Hair loss can be frustrating and, at times, alarming for both men and women. While genetics, stress, and hormones play major ...

The regulatory greenlight was backed by two Phase III trials that showed normalized growth hormone levels in patients with ...

The U.S. Food and Drug Administration approved Crinetics Pharmaceuticals' drug to treat a rare hormonal disorder on Thursday, ...

Attackers are increasingly exploiting generative AI by embedding malicious prompts in macros and exposing hidden data through parsers. The switch in adversarial tactics — noted in a recent State of ...

CLEVELAND, Ohio (WOIO) -The incredible number of people dropping weight rapidly with injections is having a positive effect on their overall health. But it’s also calling for post-GLP-1 surgeries.

A recent report by the Institute for Clinical and Economic Review highlights the improved cost-effectiveness of GLP-1 weight-loss injections, notably semaglutide (Ozempic, Wegovy) and tirzepatide ...

GLP-1 receptor agonists—the popular class of weight-loss drugs that include semaglutide (Ozempic)—may carry underrecognized risks for women of reproductive age, according to new research from ...